End Stage Renal Disease — A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
Citation(s)
A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis